Clinical trials: Diabetic Peripheral Neuropathic Pain (DPNP)
Diabetic Peripheral Neuropathy (DPN), Diabetic Peripheral Neuropathic Pain (DPNP)
Using Lymphovenous Bypass to Alleviate Diabetic Peripheral Neuropathy
Diabetes is a metabolic disease characterized by high blood sugar levels due to a lack of insulin. Long-term metabolic disorders can cause structural and functional changes in many organs, mainly affecting the vascular system…
- Conditions
- Diabetic Peripheral Neuropathy (DPN), Diabetic Peripheral Neuropathic Pain (DPNP), Diabetic Foot Ulcer
- Trial name
- LVB ease DPN (NCT07126197)
- Testing
- lymphovenous bypass at diseased foot dorsum
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Diabetic Peripheral Neuropathic Pain
A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)
The main purpose of this study is to evaluate the effectiveness and safety of the study drug known as duloxetine in participants with diabetic peripheral neuropathic pain.
- Trial name
- NCT02417935
- Testing
- Duloxetine, Pregabalin
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Neuropathic Pain, Diabetes
Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
The hypothesis of this Phase 2 study is that at least 1 dose regimen of DS-1971a will demonstrate clinical superiority to placebo in managing pain associated with DPNP, and will be generally well tolerated.
- Trial name
- NCT02673866
- Testing
- DS-1971a, pregabalin
- Sponsor
- Daiichi Sankyo
Diabetic Peripheral Neuropathic Pain (DPNP)
Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain
The goal of this clinical trial is to learn if drug Mirogabalin works to treat diabetic peripheral neuropathic pain in adults. It will also learn about the safety of the drug Mirogabalin.
- Trial name
- NCT07451431
- Testing
- Mirogabalin, Pregabalin
- Where
- Bangladesh
- Volunteers
- 78 people
- Sponsor
- Bangladesh Medical University
Diabetic Peripheral Neuropathic Pain (DPNP)
YJ001 Spray for Diabetic Peripheral Neuropathic Pain
The goal of this clinical trial is to learn if YJ001 Spray works to treat diabetic patients with Diabetic Peripheral Neuropathic Pain..It will also learn about the safety of drug YJ001 Spray.This trial is divided into two parts.
- Trial name
- NCT07859111
- Testing
- YJ001 spray simulant, YJ001 spray, Crisugabalin Besilate Capsules
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
Pain, Diabetic Neuropathies
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain
The objective of this study is to investigate the safety and efficacy of an investigational drug, V3381, for the treatment of diabetic peripheral neuropathic (DPN) pain (pain in one's feet and legs, or even in one's hands and…
- Trial name
- NCT00375960
- Testing
- V3381
- Where
- 6 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Vernalis (R&D) Ltd
Pain
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain
This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic…
- Trial name
- NEPTUNE-17 (NCT05838755)
- Testing
- GSK3858279
- Where
- 81 sites in United States, Canada and 9 more
- Volunteers
- 147 people
- Sponsor
- GlaxoSmithKline
Diabetic Peripheral Neuropathic Pain
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD)…
- Trial name
- NCT06361108
- Testing
- YJ001 for Spray Use
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
Diabetic Peripheral Neuropathic Pain
A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
This study will evaluate the safety and effectiveness of mirogabalin in adult patients with diabetic peripheral neuropathic pain (DPNP) in real-world clinical practice setting in China.
- Trial name
- NCT06812117
- Testing
- No Drug
- Where
- 43 sites in China
- Volunteers
- 721 people
- Sponsor
- Daiichi Sankyo
Diabetic Neuropathies
Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from Diabetic Neuropathy.
- Trial name
- NCT00322621
- Testing
- Duloxetine
- Where
- 19 sites in Brazil, France and 2 more
- Volunteers
- 216 people
- Sponsor
- Eli Lilly and Company
Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain (DPNP)
The purpose of the study is to evaluate the efficacy of study drug (BMS-954561) as compared to placebo in the treatment of patients with diabetic peripheral neuropathic pain (DPNP).
- Trial name
- NCT01314222
- Testing
- BMS-954561, Pregabalin
- Where
- 24 sites in United States, France
- Volunteers
- 178 people
- Sponsor
- Bristol-Myers Squibb
Diabetic Peripheral Neuropathic Pain
Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)
The purpose of this trial is to determine if patients suffering from diabetic peripheral neuropathic pain treated with ranolazine will have a greater reduction in pain compared to placebo.
- Trial name
- NCT02156336
- Testing
- Ranolazine
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Horizons International Peripheral Group
Diabetic Peripheral Neuropathic Pain (DPNP)
Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIb Clinical Trial of Spray YJ001 for the Treatment of Diabetic Peripheral Neuropathic Pain
The goal of this clinical trial is to learn if YJ001 Spray can treat diabetic patients with Diabetic Peripheral Neuropathic Pain(DPNP).
- Trial name
- NCT07858344
- Testing
- YJ001 spray simulator, YJ001 Spray 240 mg/day, YJ001 Spray 480 mg/day
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Zhejiang Yuejia Pharmaceuticals Co., Ltd.
Diabetic Peripheral Neuropathic Pain
A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
The primary purpose of this study is to evaluate the safety and efficacy of medical cannabis aerosol containing 0.25, 0.50, 1.0 milligrams (mg) delta (Δ) 9-tetrahydrocannabinol (THC) inhaled three times a day (TID) compared to…
- Trial name
- NCT06490445
- Testing
- Medical Cannabis
- Where
- 38 sites in Australia, Czechia and 3 more
- Volunteers
- 122 people
- Sponsor
- Syqe Medical
Diabetic Peripheral Neuropathic Pain
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/
- Trial name
- PROGRESS (NCT06203002)
- Testing
- LX9211 (blinded)
- Where
- 108 sites in United States
- Volunteers
- 496 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetic Neuropathies, Depressive Disorder, Major
Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
The primary objective is to evaluate, separately in diabetic polyneuropathic pain (DPNP) patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given as 60 mg to 120 mg once daily (QD) leads to a…
- Trial name
- NCT00844194
- Testing
- Duloxetine 60 mg QD, Duloxetine 30 mg QD, Duloxetine 90 mg QD
- Where
- 25 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Diabetic Peripheral Neuropathic Pain
Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain
Randomised, double-blind, placebo-controlled, parallel group, multicentre study of oral doses of V3381, titrated to effect. A 2-week single-blind run-in period will be followed by a 13 week double-blind titration and maintenance…
- Trial name
- NCT00794430
- Testing
- V3381
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 161 people
- Sponsor
- Vernalis (R&D) Ltd